Exiqon announces positive clinical data from EORTC clinical trial showing Oncotech EDR Assay predicts resistance to platinum-based therapy in ovarian cancer The European Organization for Research and Treatment of Cancer (EORTC) has undertaken a multi-institutional prospective randomized clinical trial on 719 late stage epithelial ovarian cancer patients (named 55971). Results were announced today at the 2008 International Gynecologic Cancer Society (IGCS) biennial meeting in Bangkok, Thailand. In this study, Oncotech EDR Assays were performed on biopsies obtained from 246 patients. Results clearly demonstrate that resistance to carboplatin, as identified by the Oncotech EDR Assay, was a significant independent predictor for response to first-line treatment in advanced ovarian cancer patients. Read the full announcement in the attached pdf-document.
Exiqon A/S announces positive clinical data from EORTC clinical trial showing Oncotech EDR Assay predicts resistance to platinum-based therapy in ovarian cancer
| Source: Exiqon A/S
Attachments
